What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis reveals differing clinical outcomes for CAR T-cell therapy in multiple myeloma, highlighting biases in response rates.

Response rates differed significantly between intention-to-treat and per-protocol analyses, highlighting bias.
Pooled overall response rate was 86% in per-protocol analyses versus 78% in intention-to-treat analyses.
Meta-analysis evaluated 46 clinical trials, involving 2,561 multiple myeloma patients and their treatment outcomes.
Results show the need for addressing clinical barriers that impede CAR T-cell treatment access for patients.

Radhakrishnan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis reveals differing clinical outcomes for CAR T-cell therapy in multiple myeloma, highlighting biases in response rates.

Response rates differed significantly between intention-to-treat and per-protocol analyses, highlighting bias.
Pooled overall response rate was 86% in per-protocol analyses versus 78% in intention-to-treat analyses.
Meta-analysis evaluated 46 clinical trials, involving 2,561 multiple myeloma patients and their treatment outcomes.
Results show the need for addressing clinical barriers that impede CAR T-cell treatment access for patients.

Radhakrishnan et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark